# Tooluniverse Clinical Trial Design

> Strategic clinical trial design feasibility assessment using ToolUniverse. Evaluates patient population sizing, biomarker prevalence, endpoint selection, comparator analysis, safety monitoring, and regulatory pathways. Creates comprehensive feasibility reports with evidence gr...

- Skill: `aipoch/tooluniverse-clinical-trial-design` (Agent Skill, multi-file: 14 files)
- Install (CLI): `npx get-skill add aipoch/tooluniverse-clinical-trial-design`
- Raw SKILL.md: https://api.skillmd.com/api/skills/aipoch/tooluniverse-clinical-trial-design/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- License: MIT
- Author: aipoch (https://skillmd.com/u/aipoch)
- Updated: 2026-09-21
- Page: https://skillmd.com/skills/aipoch/tooluniverse-clinical-trial-design

---

> **Source**: [https://github.com/aipoch/medical-research-skills](https://github.com/aipoch/medical-research-skills)


# Clinical Trial Design Feasibility Assessment

Systematically assess clinical trial feasibility by analyzing 6 research dimensions. Produces comprehensive feasibility reports with quantitative enrollment projections, endpoint recommendations, and regulatory pathway analysis.

**IMPORTANT**: Always use English terms in tool calls (drug names, disease names, biomarker names), even if the user writes in another language. Only try original-language terms as a fallback if English returns no results. Respond in the user's language.

## Core Principles

### 1. Report-First Approach (MANDATORY)
**DO NOT** show tool outputs to user. Instead:
1. Create `[INDICATION]_trial_feasibility_report.md` FIRST
2. Initialize with all section headers
3. Progressively update as data arrives
4. Present only the final report

### 2. Evidence Grading System

| Grade | Symbol | Criteria | Examples |
|-------|--------|----------|----------|
| **A** | ★★★ | Regulatory acceptance, multiple precedents | FDA-approved endpoint in same indication |
| **B** | ★★☆ | Clinical validation, single precedent | Phase 3 trial in related indication |
| **C** | ★☆☆ | Preclinical or exploratory | Phase 1 use, biomarker validation ongoing |
| **D** | ☆☆☆ | Proposed, no validation | Novel endpoint, no precedent |

### 3. Feasibility Score (0-100)
Weighted composite score:
- **Patient Availability** (30%): Population size × biomarker prevalence × geography
- **Endpoint Precedent** (25%): Historical use, regulatory acceptance
- **Regulatory Clarity** (20%): Pathway defined, precedents exist
- **Comparator Feasibility** (15%): Standard of care availability
- **Safety Monitoring** (10%): Known risks, monitoring established

**Interpretation**: ≥75 = HIGH (proceed) | 50-74 = MODERATE (validate) | <50 = LOW (de-risk)

→ Detailed scoring rules: [references/scoring_and_endpoints.md](references/scoring_and_endpoints.md)

---

## When to Use This Skill

Apply when users:
- Plan early-phase trials (Phase 1/2 emphasis)
- Need enrollment feasibility assessment
- Design biomarker-selected trials
- Evaluate endpoint strategies
- Assess regulatory pathways
- Compare trial design options
- Need safety monitoring plans

**Trigger phrases**: "clinical trial design", "trial feasibility", "enrollment projections", "endpoint selection", "trial planning", "Phase 1/2 design", "basket trial", "biomarker trial"

**NOT for**:
- Patient-to-trial matching → use `tooluniverse-clinical-trial-matching`
- Phase 3/4 confirmatory trial design → needs specialized biostatistics consultation
- Post-market surveillance or pharmacovigilance → use `tooluniverse-adverse-event-detection`
- Regulatory submission document preparation → use specialized regulatory affairs tools

---

## Quick Start

```python
from tooluniverse import ToolUniverse

tu = ToolUniverse(use_cache=True)
tu.load_tools()

# Example: EGFR+ NSCLC trial feasibility
indication = "EGFR-mutant non-small cell lung cancer"
biomarker = "EGFR L858R"

# Step 1: Get disease prevalence
disease_info = tu.tools.OpenTargets_get_disease_id_description_by_name(
    diseaseName="non-small cell lung cancer"
)

# Step 2: Estimate biomarker prevalence
variants = tu.tools.ClinVar_search_variants(gene="EGFR", significance="pathogenic")

# Step 3: Find precedent trials
trials = tu.tools.search_clinical_trials(
    condition="EGFR positive non-small cell lung cancer",
    status="completed", phase="2"
)

# Step 4: Identify standard of care comparator
soc_drugs = tu.tools.FDA_OrangeBook_search_drugs(ingredient="osimertinib")

# Compile into feasibility report...
```

---

## Core Strategy: 6 Research Paths

Execute 6 parallel research dimensions:

```
Trial Design Query (e.g., "EGFR+ NSCLC trial, Phase 2, ORR endpoint")
│
├─ PATH 1: Patient Population Sizing
│   Disease prevalence → Biomarker prevalence → Eligibility funnel → Enrollment projection
│
├─ PATH 2: Biomarker Prevalence & Testing
│   Mutation frequency → CDx availability → Turnaround time → Alternative biomarkers
│
├─ PATH 3: Comparator Selection
│   Standard of care → Approved comparators → Historical controls → Placebo appropriateness
│
├─ PATH 4: Endpoint Selection
│   Primary endpoint precedents → FDA acceptance → Measurement feasibility → Surrogate vs clinical
│
├─ PATH 5: Safety Endpoints & Monitoring
│   Mechanism-based toxicity → Class effects → Organ monitoring → SMC plan
│
└─ PATH 6: Regulatory Pathway
    Regulatory precedents → Breakthrough potential → Orphan designation → FDA guidance
```

→ Detailed execution instructions & tool calls: [references/research_paths_detail.md](references/research_paths_detail.md)

---

## Report Structure (14 Sections)

Create `[INDICATION]_trial_feasibility_report.md` with:

### 1. Executive Summary
```markdown
# Clinical Trial Feasibility Report: [INDICATION]
**Date**: [YYYY-MM-DD] | **Trial Type**: [Phase 1/2] | **Primary Endpoint**: [ORR]
**Feasibility Score**: [0-100] - [LOW/MODERATE/HIGH]

## Key Findings
- **Patient Availability**: [Est. enrollable patients/year]
- **Enrollment Timeline**: [Months to target N]
- **Endpoint Precedent**: [Grade A/B/C/D]
- **Regulatory Pathway**: [505(b)(1), breakthrough, orphan]
- **Critical Risks**: [Top 3]

## Go/No-Go Recommendation
[RECOMMEND PROCEED / ADDITIONAL VALIDATION / DO NOT RECOMMEND]
```

### 2. Disease Background — Indication, prevalence, SOC, unmet need
### 3. Patient Population Analysis — Funnel model with enrollment projections
### 4. Biomarker Strategy — Prevalence, CDx, logistics
### 5. Endpoint Selection & Justification — Primary/secondary/exploratory with evidence grades
### 6. Comparator Analysis — SOC, design options, drug sourcing
### 7. Safety Endpoints & Monitoring Plan — DLT, toxicities, organ monitoring, SMC
### 8. Study Design Recommendations — Phase, schema, eligibility, treatment plan, schedule
### 9. Enrollment & Site Strategy — Site selection, projections, recruitment
### 10. Regulatory Pathway — FDA pathway, precedents, pre-IND, IND timeline
### 11. Budget & Resource Considerations — Cost drivers, FTE requirements
### 12. Risk Assessment — Feasibility risks, scientific risks, mitigation
### 13. Success Criteria & Go/No-Go Decision — Phase 1/2 criteria, scorecard
### 14. Recommendations & Next Steps — Final recommendation, critical path, alternatives

→ Detailed section templates: [references/research_paths_detail.md](references/research_paths_detail.md)

---

## Feasibility Scorecard Template

```markdown
| Dimension | Weight | Score (0-10) | Weighted | Grade |
|-----------|--------|--------------|----------|-------|
| Patient Availability | 30% | [X] | [0.30×X] | [★★☆] |
| Endpoint Precedent | 25% | [X] | [0.25×X] | [★★★] |
| Regulatory Clarity | 20% | [X] | [0.20×X] | [★★☆] |
| Comparator Feasibility | 15% | [X] | [0.15×X] | [★★★] |
| Safety Monitoring | 10% | [X] | [0.10×X] | [★★☆] |
| **TOTAL** | **100%** | - | **[XX/100]** | - |
```

→ Full scoring algorithm & dimension guides: [references/scoring_and_endpoints.md](references/scoring_and_endpoints.md)

---

## Output Format Requirements

### Report File Naming
- `[INDICATION]_trial_feasibility_report.md`
- Example: `EGFR_L858R_NSCLC_trial_feasibility_report.md`

### Section Completeness
All 14 sections MUST be present (listed above).

### Evidence Grading Required In
Sections 1, 4, 5, 6, 7, 10, 13 — all key claims must carry evidence grades (★★★/★★☆/★☆☆/☆☆☆).

### Feasibility Score Transparency
Show calculation with raw scores, weights, and evidence sources.

---

## Tool Quick Reference

| Path | Primary Tools |
|------|--------------|
| PATH 1 | `OpenTargets_get_disease_id_description_by_name`, `OpenTargets_get_diseases_phenotypes`, `ClinVar_search_variants`, `gnomAD_search_gene_variants` |
| PATH 2 | `ClinVar_get_variant_details`, `COSMIC_search_mutations`, `gnomAD_get_variant_details` |
| PATH 3 | `drugbank_get_drug_basic_info_by_drug_name_or_id`, `FDA_OrangeBook_search_drugs`, `FDA_get_drug_approval_history` |
| PATH 4 | `search_clinical_trials`, `PubMed_search_articles`, `FDA_get_drug_approval_history` |
| PATH 5 | `drugbank_get_pharmacology_by_drug_name_or_drugbank_id`, `FAERS_search_reports_by_drug_and_reaction`, `FAERS_count_reactions_by_drug_event` |
| PATH 6 | `FDA_get_drug_approval_history`, `PubMed_search_articles`, `search_clinical_trials` |

All tools accessed via `tu.tools.<tool_name>(<params>)`. Use English for all query parameters.

---


## Input Validation

This skill accepts requests that match the documented purpose of `tooluniverse-clinical-trial-design` and include enough context to complete the workflow safely.

Do not continue the workflow when the request is out of scope, missing a critical input, or would require unsupported assumptions. Instead respond:

> `tooluniverse-clinical-trial-design` only handles its documented workflow. Please provide the missing required inputs or switch to a more suitable skill.

## References

| File | Content |
|------|---------|
| [references/research_paths_detail.md](references/research_paths_detail.md) | 6 Research Path detailed execution instructions, step-by-step code, report templates, tool references |
| [references/scoring_and_endpoints.md](references/scoring_and_endpoints.md) | Feasibility Score complete algorithm, dimension scoring criteria, endpoint selection decision tree, success criteria definitions |
| [references/examples_and_troubleshooting.md](references/examples_and_troubleshooting.md) | Complete EGFR L858R example, 5 use cases, common pitfalls, best practices, integration guide |

## Error Handling

- If required inputs are missing, state exactly which fields are missing and request only the minimum additional information.
- If the task goes outside the documented scope, stop instead of guessing or silently widening the assignment.
- If execution fails, report the failure point, summarize what can still be completed safely, and provide a manual fallback.
- Do not fabricate files, citations, data, search results, or execution outcomes.

